ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment

ImageneBio, Inc.

2025-Q3 EPS reported -$9.98 revenue$800,000

Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.
Phase 2b ADAPTIVE trial protocol amendment to expand dosing regimens; topline data expected in 2027; enrollment ongoing.
New alopecia areata data (Phase 1b/2a) and atopic dermatitis data to be presented at ISDS Nov 12-15, 2025.
Completed reverse merger with Ikena Oncology and $75M private placement; new CEO Kristin Yarema, CSO Kurinji Pandiyan, CTO Renuka Sivendran, and independent director Joe Slattery.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-275910
form_type: 8-K
ticker: IMA
cik: 0001835579
company_name: ImageneBio, Inc.
filed_at: 2025-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.713807+00:00
generated_at: 2026-05-16T21:30:58.171367+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-275910
json_url: https://secwatch.observer/filing/0001193125-25-275910.json
markdown_url: https://secwatch.observer/filing/0001193125-25-275910.md
text_url: https://secwatch.observer/filing/0001193125-25-275910.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/0001193125-25-275910-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-275910

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.